SRR934819
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 120.89356110381077
- age_years
- 40
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.455
- NOTCH_SIGNALING+0.430
- MYC_TARGETS_V1+0.404
- E2F_TARGETS+0.403
- G2M_CHECKPOINT+0.368
- INTERFERON_GAMMA_RESPONSE+0.360
- UNFOLDED_PROTEIN_RESPONSE+0.348
- PROTEIN_SECRETION+0.340
- MTORC1_SIGNALING+0.337
- MITOTIC_SPINDLE+0.333
Top 10 suppressed
- KRAS_SIGNALING_DN-0.333
- SPERMATOGENESIS-0.248
- APICAL_SURFACE-0.239
- MYOGENESIS-0.203
- ANGIOGENESIS-0.128
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.114
- APICAL_JUNCTION-0.093
- COAGULATION-0.042
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.026
- HYPOXIA-0.005
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 0F8BE394-BA6A-401C-87D0-9B3CF50FB0C8 | — | — | 0.926 |
| 2 | SRR934754 | — | — | 0.919 |
| 3 | 8EFB3C39-094A-4F91-8B8D-EE8A32AC7E1F | — | — | 0.910 |
| 4 | SRR934764 | — | — | 0.900 |
| 5 | SRR934756 | — | — | 0.900 |
| 6 | 745233F1-DF41-4DDA-9146-1666DD59355E | — | — | 0.899 |
| 7 | 8BA4F4D7-5FCD-42B8-B000-108067FE6885 | — | — | 0.898 |
| 8 | C969CDC5-D2DC-4F7B-B84B-C53CEF26B2CF | — | — | 0.897 |
| 9 | 57AA1143-0FA1-4197-8CBE-517F6B885753 | — | — | 0.895 |
| 10 | E6AA40DA-9AB7-478B-B46B-827F9AFE52D1 | — | — | 0.893 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.455 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.430 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.404 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.403 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.368 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.360 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.348 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.340 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.337 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.333 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.331 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.329 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.313 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.285 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.248 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.247 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.241 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.229 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.182 | Inavolisib | — uncovered |